Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine
Abstract
Atypical teratoid/rhabdoid tumors (AT/RT) are aggressive infantile brain tumors with poor survival. Recent advancements have highlighted significant molecular heterogeneity in AT/RT with an aggressive subgroup featuring overexpression of the MYC proto-oncogene. We perform the first comprehensive metabolic profiling of patient-derived AT/RT cell lines to identify therapeutic susceptibilities in high MYC-expressing AT/RT.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 01, 2019
- Source ID
- 10.1158/1078-0432.ccr-19-0189
Entities
People
- Allison R. Hanaford
- Antoinette Price
- Barbara S. Slusher
- Brad Poore
- Brent A Orr
- Charles G. Eberhart
- Eric H. Raabe
- Harpreet Kaur
- Jeffrey A. Rubens
- Jesse Alt
- Sabrina Wang
- Sariah J. Allen
Organizations
- Alex's Lemonade Stand Foundation
- Johns Hopkins University
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke
- St. Jude Children's Research Hospital
- United States Department of Defense